Diarrhea News and Research

Latest Diarrhea News and Research

Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Noroviruses are a group of viruses. They're the leading cause of gastroenteritis, which causes diarrhea and vomiting. They affect the whole age range from young children to the elderly, and, in the US, they cause about 20 million cases annually.

28 Jul 2014

Researchers examine effects of bacteria in fighting against obesity

A probiotic that prevents obesity could be on the horizon. Bacteria that produce a therapeutic compound in the gut inhibit weight gain, insulin resistance and other adverse effects of a high-fat diet in mice, Vanderbilt University investigators have discovered.

26 Jul 2014

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union.

25 Jul 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

18 Jul 2014

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

17 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014

Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

10 Jul 2014

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection.

10 Jul 2014

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Researchers have found that fecal transplantation is effective and safe for treating C. difficile in immunocompromised patients. This is the result of a study led by Colleen Kelly, M.D., a gastroenterologist in the Center for Women's Gastrointestinal Medicine at The Women's Medicine Collaborative.

10 Jul 2014

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.

9 Jul 2014

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Genetic variants linked with greater risk for radiation-driven side effects in cancer patients

Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study published this week in Nature Genetics.

8 Jul 2014

Samples from Chobani yogurt contain most virulent form of fungus

Samples isolated from Chobani yogurt that was voluntarily recalled in September 2013 have been found to contain the most virulent form of a fungus called Mucor circinelloides, which is associated with infections in immune-compromised people.

8 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

7 Jul 2014

Treating ulcerative colitis and Crohn’s disease

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.

7 Jul 2014

Researchers find novel inhibitor that prevents cholera toxin from binding to carbohydrates

Cholera against cholera: a novel inhibitor prevents the cholera toxin from binding to carbohydrates found on the surface of intestinal cells.

7 Jul 2014

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Consumers worldwide spend billions of dollars each year on probiotic foods and supplements. But studies evaluating probiotics - microorganisms believed to aid digestive health - have been limited.

4 Jul 2014

Diarrhea News and Research

Latest Diarrhea News and Research

Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Researchers examine effects of bacteria in fighting against obesity

EMA recommends full marketing approval for IMBRUVICA in the European Union

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Pain control in osteoarthritis patients

Genetic variants linked with greater risk for radiation-driven side effects in cancer patients

Samples from Chobani yogurt contain most virulent form of fungus

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Treating ulcerative colitis and Crohn’s disease

Researchers find novel inhibitor that prevents cholera toxin from binding to carbohydrates

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Pharmaceutical Manufacturing - Industry Focus eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Diarrhea News and Research

Latest Diarrhea News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in